Cellectar Biosciences (CLRB) risk factors
Item 1A of every Cellectar Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors45 risks5 new7 dropped6 reworded
The company added disclosures on supplier dependencies, EU drug legislation reforms, and stock price compliance. Financial restatement disclosures were expanded to cover additional quarters. Nasdaq minimum stockholders' equity requirements were added to listing risks.
Filed Mar 04, 2026 - FY2024 10-K risk factors47 risks
Operating cash of $23.3 million funds operations only into the fourth quarter of 2025. Financial statement restatements for 2022 and 2023 expose the company to legal and regulatory risks. Dependence on third-party contract research organizations and outsourced manufacturing creates operational vulnerabilities.
Filed Mar 13, 2025